Albany, NY -- (SBWIRE) -- 08/29/2019 -- Adenoid Cystic Carcinoma Market Insights, Epidemiology and Market Forecast-2028
1. Adenoid cystic carcinoma of the salivary glands, the most common form of the disease, is thought to account for approximately 25 percent of malignant salivary gland tumors.
2. There are approximately 566,000 people diagnosed with cancer in the US each year, and only about 1224 of them are diagnosed with Adenoid cystic carcinoma.
3. Adenoid cystic carcinoma has a global incidence of 3 to 4.5 cases per million per year.
DelveInsight launched a new report on Adenoid cystic carcinoma Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Adenoid cystic carcinoma market report covers a descriptive overview and comprehensive insight of the Adenoid cystic carcinoma epidemiology and Adenoid cystic carcinoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Adenoid cystic carcinoma market report provides insights on the current and emerging therapies.
3. Adenoid cystic carcinoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Adenoid cystic carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Adenoid cystic carcinoma market.
Request for sample pages
"Adenoid cystic carcinoma of the lower respiratory tract accounts for less than one percent (0.1 to 0.2 per cent) of all primary lung tumours."
In the current Adenoid cystic carcinoma market scenario, the standard Adenoid cystic carcinoma treatment includes Surgery followed by radiation therapy and Medical therapy. Surgery followed by radiation therapy is the most common Adenoid cystic carcinoma treatment. In large number of cases Surgery and radiation therapy are standard Adenoid cystic carcinoma treatments to stop the cancer and avoid recurrence. Radiation therapy for the residual cells is the most common Adenoid cystic carcinoma treatment. In advanced stage of Adenoid Cystic Carcinoma, medical therapy is the first line of treatment.
Due to its complicated clinical course and vague etiology, medical therapy is not standardized for Adenoid cystic carcinoma, yet radical excision and postop-radiation is mainly utilized for loco-regional control for early stage disease.
Currently, there are no approved drugs for Adenoid Cystic Carcinoma treatment. Due to rarity of Adenoid Cystic Carcinoma, there are no disease specific agents designed for Adenoid Cystic Carcinoma treatment. Therefore, drugs that are currently used for more common cancers have been attempted on patients with Adenoid Cystic Carcinoma based on molecular findings, targeting the same markers identified in other cancers. Most of these agents used in Adenoid Cystic Carcinoma treatment are in phase I or II clinical trials and current chemotherapy give low response rate.
The launch of the emerging therapies is expected to significantly impact Adenoid Cystic Carcinoma treatment scenario in the upcoming years:-
Drugs covered
1. CB-103
2. Dovitinib
3. AL101
And many others
The key players in Adenoid Cystic Carcinoma market are:
1. CureVac
2. Ayala
3. Oncology Venture
4. Cellestia Biotech
And many others
Table of contents
1. Report Introduction
2. Adenoid Cystic Carcinoma Market Overview at a Glance
3. Adenoid Cystic Carcinoma Disease Background and Overview
4. Adenoid Cystic Carcinoma Epidemiology and Patient Population
5. Adenoid Cystic Carcinoma Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.Spain
5.2.5.United Kingdom
5.3. Japan
6. Adenoid Cystic Carcinoma Treatment & Medical Practices
7. Adenoid Cystic Carcinoma Emerging Therapies
7.1. Key Cross Competition
7.2. CB-103:Cellestia Biotech
7.3. AL101:Ayala
7.4. Dovitinib: Oncology Venture
8. Adenoid Cystic Carcinoma Market Size
9. 7MM Adenoid Cystic Carcinoma Country-Wise Market Analysis
9.1. United States
9.2. Germany
9.3. France
9.4. United Kingdom
9.5. Spain
9.6. Italy
9.7. Japan
10. Adenoid Cystic Carcinoma Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight